Some HIV-positive women in Canada have poorer responses to therapy

Potent combination therapy for HIV (commonly called ART or HAART) can improve and maintain the health of people who use it. In Canada and similar countries researchers have found that the benefits of ART are so tremendous that rates of AIDS-related infections and deaths associated with AIDS have significantly declined since 1996. Furthermore, researchers predict that a young adult who is infected today and is diagnosed and initiates treatment shortly thereafter and who is engaged in their care and treatment and does not have co-morbidities (such as untreated or poorly managed depression, schizophrenia, addiction or co-infections) is likely to survive for several decades.

Focus on women

Although there have been massive reductions in AIDS-related illnesses and deaths, other troubling trends exist. For instance, in the past decade thousands of new HIV infections have occurred in Canada and women now make up nearly 25% of the population with this infection. As a comparison, in the first two decades of the HIV epidemic in Canada, women comprised 12% of cases.

In three provinces-A summary

Researchers in three provinces-British Columbia, Ontario and Quebec-recently analysed health-related information collected from 5,442 HIV-positive people since the year 2000. The researchers found that women generally began ART at an earlier age than men and that women were more likely than men to disclose that they injected street drugs. However, regardless of their history of injecting drugs, women in this study were less likely than men to achieve an HIV viral load less than 50 copies/ml. Furthermore, even if they did manage to get their viral load below the 50-copy threshold, women were more likely to have this degree of virologic control as a temporary event, as their viral loads would eventually rise above the 1,000 copies/ml level.

Sean R. Hosein
CATIE
Read More

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below